PE20220250A1 - Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma - Google Patents

Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma

Info

Publication number
PE20220250A1
PE20220250A1 PE2021001049A PE2021001049A PE20220250A1 PE 20220250 A1 PE20220250 A1 PE 20220250A1 PE 2021001049 A PE2021001049 A PE 2021001049A PE 2021001049 A PE2021001049 A PE 2021001049A PE 20220250 A1 PE20220250 A1 PE 20220250A1
Authority
PE
Peru
Prior art keywords
docetaxel
ritonavir
cancer
treatment
plasma
Prior art date
Application number
PE2021001049A
Other languages
English (en)
Spanish (es)
Inventor
Jacob Hendrik Beijnen
Johannes Henricus Matthias Schellens
Original Assignee
Modra Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modra Pharmaceuticals B V filed Critical Modra Pharmaceuticals B V
Publication of PE20220250A1 publication Critical patent/PE20220250A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2021001049A 2018-12-21 2019-12-18 Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma PE20220250A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18215472 2018-12-21
PCT/EP2019/086124 WO2020127606A1 (en) 2018-12-21 2019-12-18 Cancer treatment using docetaxel by controlling peak plasma levels

Publications (1)

Publication Number Publication Date
PE20220250A1 true PE20220250A1 (es) 2022-02-16

Family

ID=64901394

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001049A PE20220250A1 (es) 2018-12-21 2019-12-18 Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma

Country Status (14)

Country Link
US (3) US20220079910A1 (enExample)
EP (2) EP3897610B1 (enExample)
JP (3) JP2022515249A (enExample)
KR (1) KR20220002860A (enExample)
CN (1) CN113543781A (enExample)
AU (2) AU2019410060A1 (enExample)
BR (1) BR112021012255A2 (enExample)
CA (1) CA3124316C (enExample)
CL (1) CL2021001638A1 (enExample)
ES (1) ES3026709T3 (enExample)
IL (1) IL284213A (enExample)
MX (2) MX2021007478A (enExample)
PE (1) PE20220250A1 (enExample)
WO (1) WO2020127606A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3897610B1 (en) * 2018-12-21 2025-04-16 Modra Pharmaceuticals B.V. Cancer treatment using docetaxel by controlling peak plasma levels
PE20220129A1 (es) * 2018-12-21 2022-01-27 Modra Pharmaceuticals B V Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
KR101544498B1 (ko) * 2007-08-24 2015-08-17 스티칭 허트 네덜란드 칸커 인스티튜트 종양성 질환의 치료를 위한 조성물
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
WO2010020799A2 (en) 2008-08-22 2010-02-25 Slotervaart Participaties Bv Composition
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
EP3897610B1 (en) * 2018-12-21 2025-04-16 Modra Pharmaceuticals B.V. Cancer treatment using docetaxel by controlling peak plasma levels
PE20220129A1 (es) * 2018-12-21 2022-01-27 Modra Pharmaceuticals B V Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a

Also Published As

Publication number Publication date
CN113543781A (zh) 2021-10-22
MX2025008270A (es) 2025-08-01
EP3897610A1 (en) 2021-10-27
KR20220002860A (ko) 2022-01-07
IL284213A (en) 2021-08-31
US20220323399A1 (en) 2022-10-13
JP2025094189A (ja) 2025-06-24
EP3897610B1 (en) 2025-04-16
EP4670718A3 (en) 2026-03-04
US20220079910A1 (en) 2022-03-17
EP4670718A2 (en) 2025-12-31
JP2023102787A (ja) 2023-07-25
CA3124316A1 (en) 2020-06-25
EP3897610C0 (en) 2025-04-16
BR112021012255A2 (pt) 2021-09-28
JP2022515249A (ja) 2022-02-17
ES3026709T3 (en) 2025-06-12
US20250312305A1 (en) 2025-10-09
WO2020127606A1 (en) 2020-06-25
CA3124316C (en) 2023-07-04
MX2021007478A (es) 2021-10-13
US11571408B2 (en) 2023-02-07
AU2019410060A1 (en) 2021-08-05
CL2021001638A1 (es) 2022-04-22
AU2023204682A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
PE20211961A1 (es) Terapia de combinacion de radioinmunoconjugados con inhibidores de danos y reparaciones del adn
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
MX2022012146A (es) Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX392707B (es) LINFOCITOS T ACTIVADOS POR BiTE EX VIVO.
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
MX2019002564A (es) Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
MX2020011727A (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de los mismos.
CL2020002993A1 (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019)
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2023001298A (es) Combinaciones para el tratamiento de cancer.
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2017015532A (es) Terapia de combinacion pac-1.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
UY33790A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.
CL2021001638A1 (es) Tratamiento del cáncer con docetaxel controlando los niveles plasmáticos máximos
CL2021001635A1 (es) Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a